Published in BMC Cancer on December 23, 2014
BRAF-Activated Long Noncoding RNA Modulates Papillary Thyroid Carcinoma Cell Proliferation through Regulating Thyroid Stimulating Hormone Receptor. Cancer Res Treat (2015) 0.84
Identification and characterization of PKF118-310 as a KDM4A inhibitor. Epigenetics (2016) 0.77
The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children. J Neurooncol (2017) 0.76
Global analysis of H3K27me3 as an epigenetic marker in prostate cancer progression. BMC Cancer (2017) 0.75
SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer. Oncogene (2016) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Simultaneous inference in general parametric models. Biom J (2008) 23.64
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Phenotypic plasticity and the epigenetics of human disease. Nature (2007) 10.37
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (2008) 7.59
Global histone modification patterns predict risk of prostate cancer recurrence. Nature (2005) 7.03
Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet (2008) 5.08
Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science (2005) 3.80
Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell (2012) 3.65
Polycomb group complexes--many combinations, many functions. Trends Cell Biol (2009) 2.36
Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res (2000) 2.16
SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res (2005) 2.07
Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res (2002) 1.74
Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res (2001) 1.72
Roles of the Polycomb group proteins in stem cells and cancer. Cell Death Dis (2011) 1.70
Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res (2009) 1.68
Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget (2011) 1.52
The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids (2007) 1.46
Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. Clin Cancer Res (2010) 1.38
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther (2007) 1.32
Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther (2005) 1.24
The role of epigenetic modifications in retinoic acid receptor beta2 gene expression in human prostate cancers. Lab Invest (2001) 1.06
EZH2, an epigenetic driver of prostate cancer. Protein Cell (2013) 1.02
Histone modifications and chromatin organization in prostate cancer. Epigenomics (2010) 0.99
Aberrant DNA methylation and prostate cancer. Curr Genomics (2011) 0.98
Frequent inactivation of axon guidance molecule RGMA in human colon cancer through genetic and epigenetic mechanisms. Gastroenterology (2009) 0.96
Soy phytoestrogens modify DNA methylation of GSTP1, RASSF1A, EPH2 and BRCA1 promoter in prostate cancer cells. In Vivo (2010) 0.96
Prostate cancer cells and bone stromal cells mutually interact with each other through bone morphogenetic protein-mediated signals. J Biol Chem (2012) 0.93
Gene promoter methylation and its potential relevance in early prostate cancer diagnosis. Pathobiology (2010) 0.91
Standards for prostate biopsy. Curr Opin Urol (2014) 0.88
Collaboration of Kras and androgen receptor signaling stimulates EZH2 expression and tumor-propagating cells in prostate cancer. Cancer Res (2012) 0.88
DNA methylation associated with polycomb repression in retinoic acid receptor β silencing. FASEB J (2013) 0.88
DNA methylation and soy phytoestrogens: quantitative study in DU-145 and PC-3 human prostate cancer cell lines. Epigenomics (2011) 0.86
miRNAs differentially expressed in prostate cancer cell lines after soy treatment. In Vivo (2011) 0.86
Methylation analysis of BRCA1, RASSF1, GSTP1 and EPHB2 promoters in prostate biopsies according to different degrees of malignancy. In Vivo (2009) 0.85
Repulsive guidance molecules, novel bone morphogenetic protein co-receptors, are key regulators of the growth and aggressiveness of prostate cancer cells. Int J Oncol (2011) 0.84
Quantitative RT-PCR analysis of estrogen receptor gene expression in laser microdissected prostate cancer tissue. Prostate (2009) 0.83
BRCA1, BRCA2, AR and IGF-I expression in prostate cancer: correlation between RT-qPCR and immunohistochemical detection. Oncol Rep (2011) 0.82
Histone lysine trimethylation or acetylation can be modulated by phytoestrogen, estrogen or anti-HDAC in breast cancer cell lines. Epigenomics (2013) 0.82
Epigenetics of prostate cancer: distribution of histone H3K27me3 biomarkers in peri-tumoral tissue. OMICS (2014) 0.81
Molecular biology. EZH2 goes solo. Science (2012) 0.81
Decreased expression of stromal estrogen receptor α and β in prostate cancer. Am J Transl Res (2014) 0.81
Gene panel model predictive of outcome in patients with prostate cancer. OMICS (2013) 0.76
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst (2011) 6.11
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res (2005) 5.70
Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol (2009) 2.41
Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions. Clin Cancer Res (2013) 2.29
Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res (2004) 2.17
Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population. Eur Urol (2011) 1.87
Standardization of HER2 testing: results of an international proficiency-testing ring study. Mod Pathol (2007) 1.69
Efficacy and tolerance of one-third full dose bacillus Calmette-Guérin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study. Int J Urol (2014) 1.42
Hereditary-like urothelial carcinomas of the upper urinary tract benefit more from adjuvant cisplatin-based chemotherapy after radical nephroureterectomy than do sporadic tumours. BJU Int (2013) 1.40
Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. J Clin Oncol (2009) 1.38
Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis. J Clin Oncol (2008) 1.33
Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. J Thorac Oncol (2009) 1.15
Prophylactic oophorectomy: a morphologic and immunohistochemical study. Cancer (2003) 1.06
DNA repair gene ERCC2, XPC, XRCC1, XRCC3 polymorphisms and associations with bladder cancer risk in a French cohort. Anticancer Res (2008) 1.06
Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. Arthritis Res Ther (2009) 1.05
Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. Clin Cancer Res (2007) 1.04
Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy. Int J Oncol (2002) 1.01
HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol (2009) 0.99
Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria. J Thorac Oncol (2014) 0.98
Assessment of oncologic control obtained after open versus laparoscopic nephroureterectomy for upper urinary tract urothelial carcinomas (UUT-UCs): results from a large French multicenter collaborative study. Ann Surg Oncol (2011) 0.98
Soy phytoestrogens modify DNA methylation of GSTP1, RASSF1A, EPH2 and BRCA1 promoter in prostate cancer cells. In Vivo (2010) 0.96
Epigenetic mechanisms of breast cancer: an update of the current knowledge. Epigenomics (2014) 0.95
Epigenetic modifications in prostate cancer. Epigenomics (2014) 0.93
Immunohistochemical staining of mucin 1 in prostate tissues. In Vivo (2009) 0.91
Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH). Mod Pathol (2012) 0.91
Revascularization of traumatic renal artery dissection by endoluminal stenting: three cases. Acta Radiol (2010) 0.91
Response to 'Statins accelerate the onset of collagen type II-induced arthritis in mice'. Arthritis Res Ther (2013) 0.91
Oncological risk of laparoscopic surgery in urothelial carcinomas. World J Urol (2008) 0.90
Genetic polymorphisms in CYP1A1, CYP1B1, COMT, GSTP1 and NAT2 genes and association with bladder cancer risk in a French cohort. Anticancer Res (2009) 0.89
Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer. PLoS One (2011) 0.88
The sympathetic nervous system is involved in variant Creutzfeldt-Jakob disease. Nat Med (2003) 0.88
Non sentinel node involvement prediction for sentinel node micrometastases in breast cancer: nomogram validation and comparison with other models. Breast (2011) 0.86
Diagnosis and treatment of prostate cancers in renal-transplant recipients. Transplantation (2003) 0.86
Histopathologic and ultrastructural features and claudin expression in papillary tumors of the pineal region: a multicenter analysis. Am J Surg Pathol (2012) 0.86
miRNAs differentially expressed in prostate cancer cell lines after soy treatment. In Vivo (2011) 0.86
DNA methylation and soy phytoestrogens: quantitative study in DU-145 and PC-3 human prostate cancer cell lines. Epigenomics (2011) 0.86
Differential effects of lycopene consumed in tomato paste and lycopene in the form of a purified extract on target genes of cancer prostatic cells. Am J Clin Nutr (2010) 0.86
Ovarian epithelial dysplasia and prophylactic oophorectomy for genetic risk. Int J Gynecol Cancer (2009) 0.86
Phytoestrogen-rich diets modulate expression of Brca1 and Brca2 tumor suppressor genes in mammary glands of female Wistar rats. Cancer Res (2003) 0.85
Methylation analysis of BRCA1, RASSF1, GSTP1 and EPHB2 promoters in prostate biopsies according to different degrees of malignancy. In Vivo (2009) 0.85
Outcome and cost analysis of sacral nerve modulation for treating urinary and/or fecal incontinence. Ann Surg (2011) 0.84
Leptin induces a proliferative response in breast cancer cells but not in normal breast cells. Nutr Cancer (2014) 0.84
[Epidemiology of and risk factors for bladder cancer and for urothelial tumors]. Rev Prat (2014) 0.84
A switch from GnRH agonist to GnRH antagonist in castration-resistant prostate cancer patients leads to a low response rate on PSA. World J Urol (2012) 0.83
Metastatic breast cancer: overall survival related to successive chemotherapies. What do we gain after the third line? Cancer Invest (2009) 0.83
Orally administered isoflavones are present as glucuronides in the human prostate. Nutr Cancer (2008) 0.83
Histone lysine trimethylation or acetylation can be modulated by phytoestrogen, estrogen or anti-HDAC in breast cancer cell lines. Epigenomics (2013) 0.82
Effects of resveratrol on the expression of a panel of genes interacting with the BRCA1 oncosuppressor in human breast cell lines. Clin Chim Acta (2004) 0.82
Can soy phytoestrogens decrease DNA methylation in BRCA1 and BRCA2 oncosuppressor genes in breast cancer? OMICS (2012) 0.82
BRCA1, BRCA2, AR and IGF-I expression in prostate cancer: correlation between RT-qPCR and immunohistochemical detection. Oncol Rep (2011) 0.82
Genistein and daidzein: different molecular effects on prostate cancer. Anticancer Res (2013) 0.82
Epidermal growth factor receptor, HER-2/neu and related pathways in lung adenocarcinomas with bronchioloalveolar features. Lung Cancer (2005) 0.82
Oxysterol receptors and their therapeutic applications in cancer conditions. Expert Opin Ther Targets (2013) 0.82
Breast cancer: mechanisms involved in action of phytoestrogens and epigenetic changes. In Vivo (2012) 0.81
Epigenetics of prostate cancer: distribution of histone H3K27me3 biomarkers in peri-tumoral tissue. OMICS (2014) 0.81
[Post-traumatic secondary arteriovenous fistulae of the kidney and their embolization. Report of 3 cases]. Prog Urol (2002) 0.81
Gene signature of breast cancer cell lines treated with lycopene. Pharmacogenomics (2006) 0.81
Impact of lymphovascular invasion on oncological outcomes in patients with upper tract urothelial carcinoma after radical nephroureterectomy. BJU Int (2013) 0.81
Lxrα regulates the androgen response in prostate epithelium. Endocrinology (2012) 0.80
P-gp expression in brown trout erythrocytes: evidence of a detoxification mechanism in fish erythrocytes. Sci Rep (2013) 0.80
Coexisting chordal papillary fibroelastoma and leaflet Lambl's tumour of the mitral valve. Interact Cardiovasc Thorac Surg (2003) 0.80
Palliative transarterial embolization of renal tumors in 20 patients. Int Urol Nephrol (2007) 0.79
Epigenetic modulation of BRCA1 and BRCA2 gene expression by equol in breast cancer cell lines. Br J Nutr (2012) 0.79
Influence of preoperative factors on the oncologic outcome for upper urinary tract urothelial carcinoma after radical nephroureterectomy. World J Urol (2014) 0.79